Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1Gynecologic 1

Conditions

Ovarian Neoplasms 323Fallopian Tube Neoplasms 159Carcinoma, Ovarian Epithelial 114Endometrial Neoplasms 77Uterine Cervical Neoplasms 72Neoplasms 28Carcinoma, Non-Small-Cell Lung 24Breast Neoplasms 23Brenner Tumor 21Recurrence 19Testicular Neoplasms 17Peritoneal Neoplasms 17Stomach Neoplasms 14Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Urinary Bladder Neoplasms 10Testicular Germ Cell Tumor 10Sarcoma 10Pancreatic Neoplasms 10Lung Neoplasms 10Colorectal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Parkinson Disease 4, Autosomal Dominant Lewy Body 9Teratoma 8Ovarian Germ Cell Cancer 8Neuroectodermal Tumors, Primitive, Peripheral 8Central Nervous System Neoplasms 8Uterine Neoplasms 7Small Cell Lung Carcinoma 7Melanoma 7

Interventions

olaparib 1Paclitaxel 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Metastatic Breast Cancer × Carboplatin × Gynecologic × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡